Targeting TSLP provides upstream suppression of type 2 inflammation, addressing persistent symptom burden (sleep disturbance and activity intolerance) that may not correlate with spirometric endpoints ...
The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...
Roma, 24 ott. (Adnkronos Salute) - La rinosinusite cronica con poliposi nasale (CRSwNP) è una malattia infiammatoria complessa, caratterizzata dalla presenza di una persistente infiammazione della ...
EU Approval – The European Commission approved Tezspire (tezepelumab) as an add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results